Brenntag’s Post-Crisis Hangover Worsens as Earnings Halve and Technical Support Cracks

Brenntag's stock fell 9.5% as chemical market normalization eliminates crisis bonus; net profit halved to €265M, dividend yields 3.51%, analysts cautious.

The swift normalisation of global chemical markets is exacting a heavy toll on Brenntag, whose shares have now tumbled roughly 9.5% in the past month alone. The stock slid through its 100-day moving average mid-week, settling at €53.96, as the tailwinds from disrupted supply chains and elevated oil prices that had supercharged the distributor’s profits evaporate faster than many anticipated.

Deutsche Bank analyst Tristan Lamotte became the latest to acknowledge the shift, downgrading Brenntag from “Buy” to “Hold” and slashing his price target from €67 to €57. In a note, Lamotte pointed to the de-escalation in the Middle East as the catalyst: the easing of geopolitical tensions has stripped away the “crisis bonus” that had padded margins, leaving Brenntag’s heavy exposure to basic chemicals suddenly exposed to falling prices and rising volatility.

The fundamental deterioration is stark. For the full year 2025, revenue slipped 3.7% to €15.2 billion, while EBITDA dropped 8.6% to €1.288 billion. Net profit took the hardest hit, collapsing by roughly half to just €265 million. The weakness continued into the first quarter of 2026, with revenues coming in at €3.7 billion — down from €4.1 billion in the same period a year earlier. Net margins have shrunk to a wafer-thin 1.5%, a figure that underscores the pressure on the core distribution model.

At the root of the trouble is a rapid shift in customer behaviour. Industrial clients across Europe and North America are aggressively destocking, compressing volumes in Brenntag’s distribution business. With raw material costs declining and competition intensifying, the room for price adjustments is vanishing. The company’s distribution model thrives on pricing power and strong demand — neither of which is present today.

Amid the gloom, the dividend provides a rare anchor. Management and the supervisory board have proposed distributing the entire retained profit of €274.3 million, equating to €1.90 per share. At the current share price, that yields approximately 3.51%. The shares went ex-dividend on 21 May 2026.

Analyst sentiment reflects the prevailing caution. Of the 22 analysts covering the stock, 42% recommend a sell and another 42% advise holding, leaving only 15% with a buy rating. The relative strength index sits at 33, edging into oversold territory — a technical signal that could lure short-term bargain hunters, though any sustained recovery will depend on fundamentals.

All eyes are now on the half-year report due 12 August 2026. Management reiterated its full-year EBITDA guidance of €1.15 billion to €1.35 billion when it announced first-quarter numbers on 7 May, and insisted the transformation programme towards specialty chemicals — a higher-margin, more stable business — remains on track. Whether that shift can offset the fading crisis premium in a normalising market will be the central question for investors.